Surrozen Closes $95.1M Final Tranche, Extends Cash Runway Into 2029
SRZN has more than doubled off its 52-week low of $11.39.
Summary
Surrozen closed the second and final tranche of its March 2025 private placement, raising about $95.1 million gross. The trigger was the Oct 2 FDA clearance of the SZN-8141 IND, which the timeline already flagged as the milestone that unlocked this money. The tranche issued roughly 5.7 million shares, pre-funded warrants for about 2.5 million shares, and Series E warrants for about 4.1 million shares at an $11.54 strike — well below the current $25.14 price, so those warrants are deep in the money and represent real future dilution. Post-closing the company has about 17.8 million shares outstanding and says cash now funds operations into 2029, covering the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b work on SZN-8143. That removes the near-term financing overhang that hung over the story after the going-concern warning in the March 10-K. First patient dosing in DUET is expected in Q4 2026, with initial data in the second half of 2027.
At the time of this announcement, SRZN was trading at $25.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $295.5M. The 52-week trading range was $11.39 to $37.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.